LYEL Lyell Immunopharma, Inc.
Nasdaq · SEC CIK 1806952 · EDGAR
- Bought, last 12 months
- $25.00M 2 purchases by 2 insiders
- Sold, last 12 months
- $604.6K 27 sales by 6 insiders
- Filings on record
- 132 since 2021-09-14, latest 2026-09-10 19:37
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| ARCH Venture Partners IX Overage, L.P. | 10% | $12.50M | — |
| BERNS PAUL L | 10% | $12.50M | — |
| Seely Lynn | Pres, CEO, Dir | — | $353.1K |
| Bulis Veronica Sanchez | VP, Corp. Ctrl | — | $96.9K |
| Lee Gary K. | CSO | — | $71.7K |
| Hill Stephen J. | COO | — | $51.3K |
| Shook David | Chief Medical Off | — | $31.3K |
| Innovative Cellular Therapeutics Holdings Ltd | 10% | — | $274.30 |
Transactions 70
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 19:37 | 2026-09-10 | LYEL | Shook David | Chief Medical Off | S - Sale | $12.70 | -500 | 20.4K | -2% | -$6,350 | |
| 2026-08-25 16:06 | 2026-08-21 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $15.54 | -9,589 | 63.9K | -13% | -$149.0K | |
| 2026-08-25 16:05 | 2026-08-21 | LYEL | Hill Stephen J. | COO | S - Sale | $15.54 | -989 | 16.8K | -6% | -$15.4K | |
| 2026-08-25 16:03 | 2026-08-21 | LYEL | Lee Gary K. | CSO | S - Sale | $15.54 | -1,457 | 16.2K | -8% | -$22.6K | |
| 2026-08-11 16:21 | 2026-08-10 | LYEL | Bulis Veronica Sanchez | VP, Corp. Ctrl | S - Sale | $14.34 | -621 | 14.8K | -4% | -$8,905 | |
| 2026-08-11 16:20 | 2026-08-10 | LYEL | Lee Gary K. | CSO | S - Sale | $14.34 | -131 | 17.7K | -0.7% | -$1,879 | |
| 2026-08-11 16:18 | 2026-08-10 | LYEL | Hill Stephen J. | COO | S - Sale | $14.34 | -89 | 17.8K | -0.5% | -$1,276 | |
| 2026-08-11 16:07 | 2026-08-10 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $14.34 | -390 | 73.5K | -0.5% | -$5,593 | |
| 2026-07-27 21:14 | 2026-07-27 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | J - Other | $0.00 | -44.0K | 2.77M | -2% | $0 | |
| 2026-07-27 19:59 | 2026-07-27 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | J - Other | $0.00 | -38.5K | 2.82M | -1% | $0 | |
| T | 2026-07-20 14:55 | 2026-07-17 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | S - Sale | $13.70 | -10 | 2.86M | -0.0% | -$137 |
| T | 2026-07-17 21:45 | 2026-07-16 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | S - Sale | $13.73 | -10 | 2.86M | -0.0% | -$137.30 |
| 2026-07-01 12:37 | 2026-06-29 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | J - Other | $0.00 | -76.0K | 2.86M | -3% | $0 | |
| 2026-06-18 21:59 | 2026-06-15 | LYEL | Innovative Cellular Therapeutics Holdings Ltd | 10% | J - Other | $0.00 | -66.5K | 2.93M | -2% | $0 | |
| 2026-06-15 18:37 | 2026-05-11 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $18.91 | -388 | 73.9K | -0.5% | -$7,337 | |
| 2026-06-15 18:35 | 2026-05-11 | LYEL | Lee Gary K. | CSO | S - Sale | $18.92 | -130 | 17.8K | -0.7% | -$2,460 | |
| 2026-06-15 18:34 | 2026-05-11 | LYEL | Hill Stephen J. | COO | S - Sale | $18.92 | -89 | 17.9K | -0.5% | -$1,684 | |
| 2026-06-15 18:32 | 2026-05-11 | LYEL | Bulis Veronica Sanchez | VP, Corp. Ctrl | S - Sale | $18.91 | -217 | 15.4K | -1% | -$4,103 | |
| 2026-06-11 16:07 | 2026-06-10 | LYEL | Shook David | Chief Medical Off | S - Sale | $12.64 | -1,977 | 20.9K | -9% | -$25.0K | |
| I | 2026-03-09 | 2026-03-06 | LYEL | BERNS PAUL L | 10% | P - Purchase | $25.61 | +488.1K | 1.43M | +52% | +$12.50M |
| I | 2026-03-09 | 2026-03-06 | LYEL | ARCH Venture Partners IX Overage, L.P. | 10% | P - Purchase | $25.61 | +488.1K | 1.43M | +52% | +$12.50M |
| 2026-02-12 | 2026-02-11 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $23.39 | -7,455 | 74.3K | -9% | -$174.4K | |
| 2026-02-12 | 2026-02-11 | LYEL | Lee Gary K. | CSO | S - Sale | $23.39 | -1,671 | 16.9K | -9% | -$39.1K | |
| 2026-02-12 | 2026-02-11 | LYEL | Hill Stephen J. | COO | S - Sale | $23.39 | -1,236 | 17.8K | -6% | -$28.9K | |
| 2026-02-11 | 2026-02-10 | LYEL | Bulis Veronica Sanchez | VP, Corp. Ctrl | S - Sale | $23.12 | -254 | 15.6K | -2% | -$5,872 | |
| 2026-02-11 | 2026-02-10 | LYEL | Bulis Veronica Sanchez | VP, Corp. Ctrl | A - Grant | $0.00 | +8,750 | 15.9K | +123% | $0 | |
| D | 2026-02-11 | 2026-02-09 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +4,000 | 19.1K | +26% | $0 |
| D | 2026-02-11 | 2026-02-10 | LYEL | Hill Stephen J. | COO | S - Sale | $23.12 | -109 | 19.0K | -0.6% | -$2,520 |
| D | 2026-02-11 | 2026-02-09 | LYEL | Seely Lynn | Pres, CEO, Dir | A - Grant | $0.00 | +20.0K | 82.2K | +32% | $0 |
| D | 2026-02-11 | 2026-02-10 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $23.12 | -438 | 81.7K | -0.5% | -$10.1K |
| D | 2026-02-11 | 2026-02-09 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +4,000 | 18.8K | +27% | $0 |
| D | 2026-02-11 | 2026-02-10 | LYEL | Lee Gary K. | CSO | S - Sale | $23.12 | -147 | 18.6K | -0.8% | -$3,399 |
| M | 2026-01-06 | 2025-12-24+ | LYEL | Bulis Veronica Sanchez | VP, Corp. Ctrl | S - Sale | $35.80 | -2,072 | 8,077 | -20% | -$74.2K |
| 2025-11-12 | 2025-11-10 | LYEL | Bulis Veronica Sanchez | VP, Corp. Ctrl | S - Sale | $16.10 | -239 | 9,213 | -3% | -$3,848 | |
| 2025-11-12 | 2025-11-10 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $16.11 | -412 | 67.2K | -0.6% | -$6,637 | |
| 2025-11-12 | 2025-11-10 | LYEL | Lee Gary K. | CSO | S - Sale | $16.16 | -138 | 15.4K | -0.9% | -$2,230 | |
| 2025-11-12 | 2025-11-10 | LYEL | Hill Stephen J. | COO | S - Sale | $16.12 | -95 | 15.8K | -0.6% | -$1,531 | |
| 2025-08-22 | 2025-08-21 | LYEL | Hill Stephen J. | COO | S - Sale | $10.54 | -1,004 | 15.8K | -6% | -$10.6K | |
| 2025-08-22 | 2025-08-20 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +8,000 | 16.8K | +90% | $0 | |
| 2025-08-22 | 2025-08-21 | LYEL | Lee Gary K. | CSO | S - Sale | $10.54 | -1,453 | 15.5K | -9% | -$15.3K | |
| 2025-08-22 | 2025-08-20 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +8,000 | 17.0K | +89% | $0 | |
| 2025-08-22 | 2025-08-20 | LYEL | Seely Lynn | Pres, CEO, Dir | A - Grant | $0.00 | +40.0K | 74.8K | +115% | $0 | |
| 2025-08-22 | 2025-08-21 | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $10.54 | -7,257 | 67.6K | -10% | -$76.5K | |
| 2025-08-22 | 2025-08-20 | LYEL | Newton Charles W. | CFO | A - Grant | $0.00 | +8,000 | 16.8K | +91% | $0 | |
| 2025-08-22 | 2025-08-21 | LYEL | Newton Charles W. | CFO | S - Sale | $10.54 | -1,453 | 15.3K | -9% | -$15.3K | |
| M | 2025-08-13 | 2025-08-11+ | LYEL | Lee Gary K. | CSO | S - Sale | $10.43 | -267 | 9,093 | -3% | -$2,786 |
| M | 2025-08-13 | 2025-08-11+ | LYEL | Seely Lynn | Pres, CEO, Dir | S - Sale | $10.43 | -797 | 35.2K | -2% | -$8,315 |
| M | 2025-08-13 | 2025-08-11+ | LYEL | Newton Charles W. | CFO | S - Sale | $10.43 | -267 | 8,895 | -3% | -$2,786 |
| M | 2025-08-13 | 2025-08-11+ | LYEL | Hill Stephen J. | COO | S - Sale | $10.43 | -185 | 8,849 | -2% | -$1,930 |
| D | 2025-06-11 | 2025-06-09 | LYEL | Shook David | Chief Medical Off | A - Grant | $0.00 | +21.9K | 21.9K | New | $0 |
| 2025-04-02 | 2025-03-31 | LYEL | BRAWLEY OTIS W | Dir | P - Purchase | $0.56 | +35.6K | 35.6K | New | +$20.0K | |
| I | 2025-03-25 | 2025-03-21 | LYEL | Ramachandra Sumant | Dir | P - Purchase | $0.58 | +200.0K | 200.0K | New | +$116.0K |
| I | 2025-03-18 | 2025-03-14 | LYEL | Klausner Richard | Dir | P - Purchase | $0.6 | +158.0K | 843.4K | +23% | +$94.8K |
| 2025-03-18 | 2025-03-14 | LYEL | Seely Lynn | Pres, CEO, Dir | P - Purchase | $0.61 | +175.0K | 712.5K | +33% | +$106.8K | |
| I | 2025-03-18 | 2025-03-17 | LYEL | Newton Charles W. | CFO | P - Purchase | $0.56 | +200.0K | 200.0K | New | +$112.0K |
| D | 2025-02-26 | 2025-02-10 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +112.5K | 176.7K | +175% | $0 |
| D | 2025-02-26 | 2025-02-10 | LYEL | Newton Charles W. | CFO | A - Grant | $0.00 | +112.5K | 172.7K | +187% | $0 |
| D | 2025-02-26 | 2025-02-10 | LYEL | Lang Matthew | Chief Business Off | A - Grant | $0.00 | +112.5K | 162.5K | +225% | $0 |
| D | 2025-02-26 | 2025-02-10 | LYEL | Seely Lynn | Pres, CEO, Dir | A - Grant | $0.00 | +337.5K | 537.5K | +169% | $0 |
| D | 2025-02-26 | 2025-02-10 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +112.5K | 172.9K | +186% | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Lang Matthew | Chief Business Off | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +40.0K | 48.9K | +448% | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Lee Gary K. | CSO | A - Grant | $0.00 | +40.0K | 52.7K | +315% | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Newton Charles W. | CFO | A - Grant | $0.00 | +40.0K | 48.7K | +458% | $0 |
| 2024-02-13 | 2024-02-09 | LYEL | Seely Lynn | Pres, CEO, Dir | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 | |
| I | 2023-08-17 | 2023-08-15 | LYEL | Klausner Richard | Dir | S - Sale | $2.28 | -58.0K | 930.9K | -6% | -$132.3K |
| I | 2022-09-27 | 2022-09-23 | LYEL | Klausner Richard | Dir | S - Sale | $6.40 | -11.1K | 988.9K | -1% | -$71.0K |
| D | 2022-09-09 | 2022-09-08 | LYEL | Bishop Hans Edgar | Dir | M - OptEx | $0.1 | +145.4K | 4.69M | +3% | +$14.5K |
| D | 2022-02-25 | 2022-02-23 | LYEL | Bishop Hans Edgar | Dir | M - OptEx | $0.1 | +993.4K | 4.54M | +28% | +$99.3K |
| MI | 2021-12-14 | 2021-12-14 | LYEL | FRIEDMAN CATHY | Dir | J - Other | $0.00 | -3.55M | 236.4K | -94% | $0 |
Purchase Sale Sale after option exercise All abbreviations